I agree that this site is using cookies. You can find further informations here.
X
Stathis, Anastasios
129  results:
OpenAccess-fulltext X
Search for persons X
?
1

P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPD..:

Caimi, Paolo F ; Ai, Weiyun Z ; Pablo Alderuccio, Juan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431093/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

PI3Kδ activation, IL6 over-expression, and CD37 loss cause ..:

Arribas, Alberto J ; Gaudio, Eugenio ; Napoli, Sara...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680772/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Results of an open-label phase 1b study of the ERK inhibito..:

Stathis, Anastasios ; Tolcher, Anthony W ; Wang, Judy S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289957/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
4

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patie..:

Hanna, Glenn ; Stathis, Anastasios ; López Miranda, Elena...
Cancer Research Communications;3(9).  , 2023
Link: https://hdl.handle.net/1..
 
?
5

Targeting myeloid chemotaxis to reverse prostate cancer the..:

Guo, Christina ; Sharp, Adam ; Gurel, Bora...
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41586-023-06696-z.  , 2023
Link: https://hdl.handle.net/2..
 
?
6

Safety and anti-tumor activity of lisavanbulin administered..:

Joerger, Markus ; Hundsberger, Thomas ; Haefliger, Simon...
https://boris.unibe.ch/178871/.  , 2023
Link: https://boris.unibe.ch/1..
 
?
7

Targeting myeloid chemotaxis to reverse prostate cancer the..:

Guo, Christina ; Sharp, Adam ; Gurel, Bora...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686834/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patie..:

Hanna, Glenn J ; Stathis, Anastasios ; Lopez-Miranda, Elena...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501326/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

Genetic and Phenotypic Attributes of Splenic Marginal Zone ..:

Bonfiglio, Ferdinando ; Bruscaggin, Alessio ; Guidetti, Francesca...
info:eu-repo/semantics/altIdentifier/pmid/34653238.  , 2022
Link: http://hdl.handle.net/24..
 
?
10

Outcome and Prognostic Factors of COVID-19 Infection in Swi..:

Joerger, Markus ; Metaxas, Yannis ; Zaman, Khalil...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14092191.  , 2022
Link: https://archive-ouverte...
 
?
11

Resistance to PI3Kδ inhibitors in marginal zone lymphoma ca..:

Arribas, Alberto J ; Napoli, Sara ; Cascione, Luciano...
Haematologica.  , 2022
Link: https://ddd.uab.cat/reco..
 
?
12

Pharmacologic screen identifies active combinations with BE..:

Spriano, Filippo ; Sartori, Giulio ; Tarantelli, Chiara...
info:eu-repo/semantics/altIdentifier/pmid/36051080.  , 2022
Link: https://hdl.handle.net/1..
 
?
13

In vitro anti-lymphoma activity of the first-in-class pan-N..:

Spriano, Filippo ; Tarantelli, Chiara ; Arribas, Alberto J...
info:eu-repo/semantics/altIdentifier/pmid/36484636.  , 2022
Link: https://hdl.handle.net/2..
 
?
14

Phase I study of lurbinectedin in combination with weekly p..:

Calvo, Emiliano ; Sessa, Cristiana ; Harada, Guilherme...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652263/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

SAKK 35/15: a phase 1 trial of obinutuzumab in combination ..:

Stathis, Anastasios ; Mey, Ulrich ; Schär, Sämi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278307/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15